Sylentis Concludes SYL040012 Phase I Trial
Sylentis claimed that the trial result was positive. In the trial, the patients demonstrated local and systemic tolerance to SYL040012. The trial’s endpoint was to determine the tolerance
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.